Rabbit Recombinant Monoclonal ENO3 antibody. Suitable for WB and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
ICC/IF | Flow Cyt | WB | IHC-P | |
---|---|---|---|---|
Human | Not recommended | Not recommended | Tested | Not recommended |
Mouse | Not recommended | Not recommended | Predicted | Not recommended |
Rat | Not recommended | Not recommended | Predicted | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 - 1/5000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Select an associated product type
Glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate. Appears to have a function in striated muscle development and regeneration.
ENO1
Beta-enolase, 2-phospho-D-glycerate hydro-lyase, Enolase 3, Muscle-specific enolase, Skeletal muscle enolase, MSE, ENO3
Rabbit Recombinant Monoclonal ENO3 antibody. Suitable for WB and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
The ENO3 protein also known as beta-enolase mechanically functions as an enzyme involved in glycolysis catalyzing the conversion of 2-phosphoglycerate to phosphoenolpyruvate. This protein has a molecular mass of approximately 47 kDa. It is specifically expressed in skeletal muscle tissue where it plays a critical role in energy metabolism. Beta-enolase is an isoform of enolase that is distinct from the alpha (ENO1) and gamma (ENO2) isoforms which have different tissue specificities.
Beta-enolase supports cellular energy production in muscles. It does not typically form part of a protein complex but acts independently in the glycolytic pathway. Its function in glycolysis is important for providing ATP to muscle cells especially during periods of high energy demand such as exercise. The efficient conversion of metabolic substrates in this pathway is essential for muscle function and maintenance.
Beta-enolase operates within the glycolytic pathway and plays an important role in energy production. This pathway is fundamental for breaking down glucose to provide ATP the energy currency of the cell. Beta-enolase works closely with other key glycolytic enzymes such as hexokinase and phosphofructokinase. Its role is indispensable in maintaining the flow of carbon through glycolysis ensuring robust energy supply for muscle contraction.
Beta-enolase is associated with diseases like glycogen storage disease type XIII and muscle-related disorders. Mutations in ENO3 gene can lead to reduced energetic efficiency and impact muscular health. Of particular note is the connection with related glycolytic proteins which may exhibit compensatory or contributing roles in these disorders. This highlights the importance of beta-enolase and its interactions in maintaining muscle physiology and energy homeostasis.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
ENO1 + ENO3 Western blot staining using rabbit Anti-ENO1 + ENO3 antibody
All lanes: Western blot - Anti-ENO1 + ENO3 antibody [EPR11366(B)] (ab157474) at 1/1000 dilution
Lane 1: HeLa cell lysate at 10 µg
Lane 2: HepG2 cell lysate at 10 µg
Lane 3: Human spleen lysate at 10 µg
Lane 4: Fetal heart lysate at 10 µg
Lane 5: Fetal muscle lysate at 10 µg
All lanes: HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 47 kDa
ENO1 + ENO3 Western blot staining of immunoprecipitation pellet from fetal muscle lysate using rabbit Anti-ENO1 + ENO3 antibody
Note: primary antibody diluted with 1% BSA.
All lanes: Western blot - Anti-ENO1 + ENO3 antibody [EPR11366(B)] (ab157474) at 1/1000 dilution
All lanes: immunoprecipitation pellet from fetal muscle lysate
All lanes: HRP-conjugated anti-rabbit IgG, which preferentially detects the non-reduced form of rabbit IgG
Predicted band size: 47 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com